Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | HRAS |
| Variant | K117N |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | HRAS K117N lies within the GTP binding domain of the Hras protein (UniProt.org). K117N has not been characterized, but can be predicted to lead to a loss of Hras protein function and activation of downstream signaling based on the effects of KRAS K117N (PMID: 20147967, PMID: 20570890, PMID: 25705018). |
| Associated Drug Resistance | |
| Category Variants Paths |
HRAS mutant HRAS act mut HRAS K117N |
| Transcript | NM_005343.4 |
| gDNA | chr11:g.533552C>G |
| cDNA | c.351G>C |
| Protein | p.K117N |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_176795.4 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_005343.4 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_005343.3 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_001130442.3 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_176795.5 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_001130442.2 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_005343 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_176795 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| NM_001130442 | chr11:g.533552C>G | c.351G>C | p.K117N | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS K117N | head and neck squamous cell carcinoma | predicted - sensitive | Tipifarnib | Preclinical - Pdx | Actionable | In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring HRAS K117N was sensitive to treatment with Zarnestra (tipifarnib), demonstrating inhibition of tumor growth, decreased cell proliferation, and reduced Erk activity (PMID: 32727882). | 32727882 |